| Literature DB >> 36119201 |
Zahra Khoshdel1, Shibi Tomas1, Marziye Jafari2.
Abstract
Objective: The main objective of the present study is to find out the loose links between prescription of medication and its utilization in the pediatric department, especially with drugs that belong to the antiepileptic medication category. Methodology: This prospective observational study was carried out for 6 months in the Department of Pharmacy Practice, Tertiary Care Hospital, Bangalore. The study was conducted on 100 patients receiving antiepileptic medication. The patient demographics and all medically relevant information were noted in a predefined data collection form.Entities:
Keywords: Antiepileptic drugs; drug utilization; epilepsy; pediatric; prescription
Year: 2022 PMID: 36119201 PMCID: PMC9480813 DOI: 10.4103/jfmpc.jfmpc_542_21
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Figure 1Distribution of different seizure types among 100 patients
Utilization of antiepileptic drugs in pediatric ward
| Drug | Gender | Total | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Male | Female | |||||
|
| ||||||
|
| % |
| % |
| % | |
| Carbamazepine | 11 | 9.4% | 9 | 7.7% | 20 | 17.1% |
| Clobazam | 3 | 2.6% | 2 | 1.7% | 5 | 4.3% |
| Clonazepam | 2 | 1.7% | 1 | 0.9% | 3 | 2.6% |
| Lamotrigine | 6 | 5.1% | 5 | 4.3% | 11 | 9.4% |
| Levetiracetam | 3 | 2.6% | 2 | 1.7% | 5 | 4.3% |
| Phenytoin | 5 | 4.3% | 3 | 2.6% | 8 | 6.8% |
| Phenobarbital | 5 | 4.3% | 4 | 3.4% | 9 | 7.7% |
| Topiramate | 5 | 4.3% | 5 | 4.3% | 10 | 8.5% |
| Valproic acid | 28 | 23.9% | 15 | 12.8% | 43 | 36.7% |
| vigabatrin | 2 | 1.7% | 1 | 0.9% | 3 | 2.6% |
| Total | 70 | 59.8% | 47 | 40.2% | 117 | 100% |
Prescription errors
| Different medication error | Total | Total (%) |
|---|---|---|
| Without generic name | 31 | 31% |
| Not in capital letter | 3 | 3% |
| Prescription not legible | 15 | 15% |
| Inappropriate abbreviations | 27 | 27% |
| Route not mentioned | 4 | 4% |
| Frequency not mentioned | 9 | 9% |
| Without signature or name of the physician | 3 | 3% |
| Mislabeling | 10 | 10% |
| Variation in dose | 9 | 9% |
Effect of important drug–drug interaction
| Drug-drug interaction | Interaction effect | Severity | Management |
|---|---|---|---|
| Carbamazepine + clonazepam | Reducing plasma levels of clonazepam | Major | Monitoring clonazepam plasma level |
| Carbamazepine + phenytoin | Decreasing phenytoin and carbamazepine concentration | Major | Monitor both dosage |
| Clonazepam + phenobarbital | Additive respiratory depression | Major | Reduction in dose of one or both drugs |
| Phenobarbital + clobazam | Additive respiratory depression | Major | Monitor both dosage |
| Carbamazepine + Ehosuximide | Loss of efficacy of ethosuximide | Moderate | Monitor, dose adjustment |
| Carbamazepine + levetiracetam | Carbamazepine toxicity | Moderate | Monitoring |
| Carbamazepine + phenobarbital | Decreased carbamazepine exposure | Moderate | Monitoring |
| Carbamazepine + Valproate acid | Carbamazepine toxicity | Moderate | Monitoring for carbamazepine |
| Ethosuximide + phenobarbital | The decreased ethosuximide serum concentration | Moderate | Monitoring |
| Ethosuximide + Valproate acid | Increased risk of ethosuximide toxicity | Moderate | Monitoring |
| Phenobarbital + Valproate acid | Phenobarbital toxicity | Moderate | Monitoring for phenobarbital toxicity |
| Phenytoin + clobazam | Increased risk of phenytoin toxicity | Moderate | Monitoring for phenytoin toxicity |
| Phenytoin + Valproate acid | Altered valproate acid | Moderate | Monitoring |
Adverse drug reactions
| Suspected drug | Effect of interaction | Incidence | Management |
|---|---|---|---|
| Levetiracetam | Loss of appetite | Monitoring | |
| Vomiting | 1 | Reduce the dose | |
| Phenytoin | Anemia | 3 | Adding vit B; Reducing the dose |
| Clobazam | Stevens–Johnson syndrome | 1 | Drug withdrawal |
Severity and mechanism of drug interaction
| Drug-drug interaction | Type of interaction | Total | Total (%) |
|---|---|---|---|
| Severity | Major | 15 | 28.8% |
| Moderate | 20 | 38.5% | |
| Minor | 17 | 32.7% | |
| Total | 52 | 100% | |
| Pharmacokinetic | Absorption | 9 | 32.2% |
| Interaction | Distribution | 5 | 17.8% |
| Metabolism | 13 | 46.5% | |
| Excretion | 1 | 3.5% | |
| Total | 28 | 100% | |
| Synergism | 18 | 70% | |
| Pharmacodynamic | Antagonism | 8 | 30% |
| Interaction | Neutralization | 0 | 0 |
| Total | 26 | 100% |